Assessment of soluble urokinase plasminogen receptor activator (suPAR) in patients admitted to the intensive care unit in a real-world setting – the SICURS study - A prospective, single center observational study

Assessment of soluble urokinase plasminogen receptor activator (suPAR) in patients admitted to the intensive care unit in a real-world setting – the SICURS study - A prospective, single center observational study - SICURS

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00022458

Enrollment

240

Registered

2020-07-15

Start date

2020-07-15

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

admission to the intensive care unit

Interventions

Group 1: Observational study / Survivor - Measurment of suPAR at admission to the ICU. After recruitment evaluation of the prognostic value of suPAR for the prediction of ICU- and 28-day mortality. Gr

Eligibility

Sex/Gender

All

Age

18 Years to 120 Years

Inclusion criteria

Inclusion criteria: - Adult (>= 18 years) patients - Admission to the ICU

Exclusion criteria

Exclusion criteria: - Declined to participate - Patient in palliative care or comfort terminal care only - Age < 18

Design outcomes

Primary

Measure	Time frame
The primary objective is to assess the prognostic value of suPAR with regards to ICU- and 28-day mortality.	—

Secondary

Measure	Time frame
Secondary objectives - Association of suPAR with coagulation markers and TEG - Association of suPAR with inflammatory markers - Association of suPAR with SOFA score - Differences between prespecified subgroups with regards to suPAR levels - Prognostic value of suPAR for LOS in the ICU and in the hospital - Prognostic value of suPAR within the different subgroups - Prognostic value of suPAR in BALF for mortality and etiology of ARDS patients - Prognostic value of suPAR in BALF for mortality of other ICU patients - Diagnostic performance of suPAR for AKI-3 - Diagnostic performance of suPAR for sepsis in the ICU - Prognostic value of initial suPAR and discharge-day-suPAR for 90-day readmission rate Prespecified subgroups: - Active hematological malignant disease - Active cancer (non-hematological) - Moderate to severe liver disease - Chronic kidney disease 3-5 - COPD GOLD 2-4 - Acute myocardial infarction - Elective valve surgery or percutaneous intervention - Continuous RRT	—

Measure

Time frame

Secondary objectives - Association of suPAR with coagulation markers and TEG - Association of suPAR with inflammatory markers - Association of suPAR with SOFA score - Differences between prespecified subgroups with regards to suPAR levels - Prognostic value of suPAR for LOS in the ICU and in the hospital - Prognostic value of suPAR within the different subgroups - Prognostic value of suPAR in BALF for mortality and etiology of ARDS patients - Prognostic value of suPAR in BALF for mortality of other ICU patients - Diagnostic performance of suPAR for AKI-3 - Diagnostic performance of suPAR for sepsis in the ICU - Prognostic value of initial suPAR and discharge-day-suPAR for 90-day readmission rate Prespecified subgroups: - Active hematological malignant disease - Active cancer (non-hematological) - Moderate to severe liver disease - Chronic kidney disease 3-5 - COPD GOLD 2-4 - Acute myocardial infarction - Elective valve surgery or percutaneous intervention - Continuous RRT

—

Countries

Austria

Contacts

Public ContactPhilipp Eller

Universitätsklinik für Innere Medizin, Medizinische Universität Graz

philipp.eller@medunigraz.at+4331638582215

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026